|
Delayed
Sao Paulo
20:50:38 25/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 63.72 BRL | +1.43% |
|
+2.51% | +11.15% |
| 08-25 | Wall Street Wants Receipts |  |
| 08-25 | Lakefront Biotherapeutics, Gilead Secure Another Orphan Drug Designation for Skin Disorder Drug in US | MT |
| Market Cap | 184B 950B 158B 148B 135B 255B 17,586B 258B 1,747B 680B 8,873B 693B 678B 29,383B | P/E 2026 * |
-45.5x | P/E 2027 * | 18.5x |
|---|---|---|---|---|---|
| Enterprise Value | 201B 1,036B 172B 162B 148B 279B 19,183B 281B 1,906B 742B 9,678B 756B 739B 32,050B | EV / Sales 2026 * |
6.56x | EV / Sales 2027 * | 5.92x |
| Free-Float |
99.88% | Yield 2026 * |
2.22% | Yield 2027 * | 2.28% |
Last Transcript: Gilead Sciences, Inc.
| 1 day | +1.43% | ||
| 1 week | +2.51% | ||
| Current month | +15.30% | ||
| 1 month | +15.67% | ||
| 3 months | +13.41% | ||
| 6 months | +1.10% | ||
| Current year | +11.15% |
| 1 week | 61.56 |  | 63.93 |
| 1 month | 54.33 | | 64.18 |
| Current year | 52.08 | | 66.06 |
| 1 year | 48.98 | | 66.06 |
| 3 years | 27.26 | | 66.06 |
| 5 years | 22.04 | | 66.06 |
| 10 years | 17.05 | | 66.06 |
| Manager | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 61 | 28/02/2019 |
Andrew Dickinson
DFI | Director of Finance/CFO | 56 | 31/10/2019 |
Keeley Wettan
CMP | Compliance Officer | - | 17/12/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kelly Kramer
BRD | Director/Board Member | 58 | 18/08/2016 |
| Director/Board Member | 73 | 31/12/2017 | |
Harish Manwani
BRD | Director/Board Member | 72 | 08/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.43% | +2.51% | - | - | 184B | |
| -3.11% | -7.11% | +61.59% | +114.71% | 1,100B | |
| -0.89% | -1.14% | +53.15% | +64.53% | 658B | |
| -1.68% | -1.96% | +25.15% | +76.87% | 470B | |
| -1.47% | +0.24% | +42.09% | +42.12% | 372B | |
| -0.90% | +0.05% | +25.57% | +40.59% | 304B | |
| -1.94% | +1.53% | +3.05% | +13.24% | 264B | |
| -0.40% | -0.71% | +51.68% | +71.20% | 239B | |
| -0.93% | +1.84% | -13.11% | -52.83% | 213B | |
| +0.04% | +0.65% | +29.46% | +92.83% | 184B | |
| Average | -0.97% | +3.01% | +30.96% | +51.47% | 422.54B | |
| Weighted average by Cap. | -1.53% | +2.21% | +40.43% | +68.14% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 30.69B 158B 26.3B 24.64B 22.51B 42.48B 2,926B 42.9B 291B 113B 1,476B 115B 113B 4,889B | 32.7B 168B 28.02B 26.25B 23.98B 45.26B 3,117B 45.7B 310B 121B 1,573B 123B 120B 5,208B |
| Net income | -4.27B -22.01B -3.66B -3.43B -3.14B -5.92B -408B -5.98B -40.49B -15.76B -206B -16.05B -15.7B -681B | 10.28B 52.91B 8.8B 8.25B 7.54B 14.22B 980B 14.36B 97.32B 37.88B 494B 38.58B 37.74B 1,637B |
| Net Debt | 16.75B 86.23B 14.35B 13.45B 12.28B 23.18B 1,596B 23.41B 159B 61.74B 805B 62.87B 61.51B 2,667B | 9.12B 46.98B 7.82B 7.33B 6.69B 12.63B 870B 12.75B 86.42B 33.64B 439B 34.26B 33.51B 1,453B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/08/26 | R$63.72 | +1.43% | 444 |
| 24/08/26 | R$62.82 | +0.27% | 444 |
| 21/08/26 | R$62.65 | +0.16% | 1,344 |
| 20/08/26 | R$62.55 | -2.02% | 206 |
| 19/08/26 | R$63.84 | +2.70% | 44 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GILD Stock
- GILD34 Stock
Select your edition
All financial news and data tailored to specific country editions
